CCOI--
COGT--
NVS--
PFE--
pfe cogent benzuclastinib breakthrough therapy
$PFE another Pfizer combo hits the market Cogent's new stomach cancer treatment cuts progression risk in half gets breakthrough therapy tag BENZINGA Jan-26-2026 10:06 a.m. ET On Monday, the FDA gave Cogent Biosciences, Inc. breakthrough therapy status for bezuclastinib paired with sunitinib in Gastrointestinal Stromal Tumors (GIST). The trial included patients who had already used Novartis AG's Gleevac (imatinib). Pfizer Inc. (PFE) sells sunitinib as Sutent.
Disclaimer: The above is a summary showing certain market information. Ainvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing, All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market.Report an Issue
CONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet